Buying More PGEN on all DipsThe market is overreacting to the NASDAQ:REPL news, and I think it’s a mistake to lump NASDAQ:PGEN in with it. Yes, PRGN-2012 is also a single-arm gene therapy trial, but it’s for an ultra-rare disease—not a broad indication like cancer. The FDA’s tougher stance seems to be focused on common diseases (like NASDAQ:REPL ’s melanoma drug), not niche, high-unmet-need therapies like Precigen’s.
Here’s why I’m loading up on this pullback:
PRGN-2012 has incredible data: 51% complete response rate, 86% reduction in surgeries (from 4 per year to zero). These patients suffer through painful, repeated procedures—this drug could be life-changing.
FDA loves it: Breakthrough Therapy, Orphan Drug, Fast Track, and Priority Review with a PDUFA date of August 27, 2025. If approved, it’ll be the first-ever treatment for RRP.
Commercial upside: Rare disease drugs have high margins, and there’s zero competition.
The sell-off is shortsighted. I’m treating this as a fire sale and buying more before the August 2025 catalyst. NASDAQ:PGEN is a high-conviction play for me.
